IN2014DN08562A - - Google Patents
Info
- Publication number
- IN2014DN08562A IN2014DN08562A IN8562DEN2014A IN2014DN08562A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A IN 8562DEN2014 A IN8562DEN2014 A IN 8562DEN2014A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A
- Authority
- IN
- India
- Prior art keywords
- sert
- prodrugs
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical compositions
- Prior art date
Links
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 abstract 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 abstract 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 abstract 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624291P | 2012-04-14 | 2012-04-14 | |
| US201261624293P | 2012-04-14 | 2012-04-14 | |
| US201261624292P | 2012-04-14 | 2012-04-14 | |
| US201261671723P | 2012-07-14 | 2012-07-14 | |
| US201261671713P | 2012-07-14 | 2012-07-14 | |
| PCT/US2013/036514 WO2013155505A1 (en) | 2012-04-14 | 2013-04-14 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08562A true IN2014DN08562A (enExample) | 2015-05-22 |
Family
ID=49328233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8562DEN2014 IN2014DN08562A (enExample) | 2012-04-14 | 2013-04-14 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US11053245B2 (enExample) |
| EP (4) | EP2836213B1 (enExample) |
| JP (6) | JP2015514135A (enExample) |
| KR (1) | KR20140146192A (enExample) |
| CN (1) | CN104519886B (enExample) |
| AU (1) | AU2013245702A1 (enExample) |
| CA (1) | CA2870303A1 (enExample) |
| ES (1) | ES2727815T3 (enExample) |
| IN (1) | IN2014DN08562A (enExample) |
| MX (1) | MX2014012374A (enExample) |
| RU (1) | RU2014145682A (enExample) |
| WO (3) | WO2013155504A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| PL2262505T3 (pl) | 2008-03-12 | 2015-04-30 | Intra Cellular Therapies Inc | Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej |
| JP6106361B2 (ja) | 2008-05-27 | 2017-03-29 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 睡眠障害および他の障害のための方法および組成物 |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| ES2727815T3 (es) | 2012-04-14 | 2019-10-18 | Intra Cellular Therapies Inc | Tratamiento del TEPT y de trastornos del control de impulsos |
| WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| PL2968320T3 (pl) | 2013-03-15 | 2021-05-17 | Intra-Cellular Therapies, Inc. | Związki organiczne |
| AU2014360452C1 (en) | 2013-12-03 | 2019-05-16 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20170012210A (ko) * | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2015154030A1 (en) * | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN104003987B (zh) * | 2014-06-03 | 2016-03-23 | 中国药科大学 | 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂 |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| US20170007618A1 (en) * | 2015-06-17 | 2017-01-12 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
| IL309536B2 (en) | 2016-01-26 | 2025-07-01 | Intra Cellular Therapies Inc | Pharmaceutical preparation for injection containing (Sa10, Rb6)-3-)8-(4-fluorophenoxy)propyl)-b6, 7, 8, 9, 10, 10a- hexahydro-H1- pyrido[3',4' :4,5]pyrrolo[1,2,3 -de]quinoxalin-2(H3)-one |
| US10688097B2 (en) | 2016-03-25 | 2020-06-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11433253B2 (en) | 2017-02-15 | 2022-09-06 | The Regents Of The University Of California | Light therapy system and methods of use |
| JP7458786B2 (ja) * | 2017-02-15 | 2024-04-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善された光療法システムおよび使用方法 |
| JP7132939B2 (ja) | 2017-03-24 | 2022-09-07 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規組成物および方法 |
| US11292793B2 (en) | 2017-04-10 | 2022-04-05 | Dr. Reddy's Laboratories Limited | Solid dispersions of amorphous Lumateperone p-Tosylate |
| US11427587B2 (en) | 2017-07-26 | 2022-08-30 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3658145A4 (en) | 2017-07-26 | 2021-04-21 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| WO2019067591A1 (en) * | 2017-09-26 | 2019-04-04 | Intra-Cellular Therapies, Inc. | NEW SALTS AND CRYSTALS |
| EP3765021A4 (en) | 2018-03-16 | 2022-03-09 | Intra-Cellular Therapies, Inc. | NOVEL PROCESSES |
| BR112020019119A2 (pt) | 2018-03-23 | 2021-01-12 | Intra-Cellular Therapies, Inc. | Compostos orgânicos |
| WO2019183546A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| IL279195B1 (en) | 2018-06-06 | 2025-08-01 | Intra Cellular Therapies Inc | A method of making bis-tosylate salt of lumateparone |
| CA3102948A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR102778034B1 (ko) * | 2018-06-11 | 2025-03-12 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| CN112585690B (zh) | 2018-06-21 | 2025-04-15 | 阿奎斯蒂弗医疗股份有限公司 | 用于制作含有药物活性物质的个性化个体单位剂量的系统和方法 |
| JP2022500362A (ja) | 2018-08-29 | 2022-01-04 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
| WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN112584837A (zh) * | 2018-08-31 | 2021-03-30 | 细胞内治疗公司 | 新方法 |
| WO2020051317A1 (en) | 2018-09-07 | 2020-03-12 | Aquestive Therapeutics, Inc. | Oral film compositions and dosage forms having precise active dissolution profiles |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12297200B2 (en) | 2018-12-17 | 2025-05-13 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| CN113423568A (zh) | 2018-12-17 | 2021-09-21 | 细胞内治疗公司 | 有机化合物 |
| US12358916B2 (en) | 2018-12-17 | 2025-07-15 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3897643B1 (en) | 2018-12-21 | 2023-11-15 | Intra-Cellular Therapies, Inc. | A pyridopyrroloquinoxaline compound and its medical use |
| MX2022000143A (es) | 2019-07-07 | 2022-02-17 | Intra Cellular Therapies Inc | Metodos novedosos. |
| EP4034119A4 (en) | 2019-09-25 | 2023-10-18 | Intra-Cellular Therapies, Inc. | NOVEL METHODS |
| AU2020373100A1 (en) | 2019-11-01 | 2022-05-19 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| BR112022008784A2 (pt) | 2019-11-14 | 2022-07-26 | Aquestive Therapeutics Inc | Composições multimodais e métodos de tratamento |
| JP7261942B2 (ja) | 2019-12-11 | 2023-04-20 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2022155544A1 (en) | 2021-01-15 | 2022-07-21 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| WO2022192476A1 (en) | 2021-03-09 | 2022-09-15 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| EP4525874A1 (en) | 2022-05-18 | 2025-03-26 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| WO2024173901A1 (en) | 2023-02-17 | 2024-08-22 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| US20250352469A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices, and methods |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US3606908A (en) | 1969-11-26 | 1971-09-21 | Trico Products Corp | Ventilation system for volatile fluid |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| JPS5014494A (enExample) * | 1973-06-11 | 1975-02-15 | ||
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| SE8304361D0 (sv) * | 1983-08-10 | 1983-08-10 | Ferrosan Ab | Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| JPS6175A (ja) * | 1984-03-06 | 1986-01-06 | ブリストル−マイア−ズ コムパニ− | 神経弛緩剤、１‐フルオロフェニルブチル‐４‐（５‐ハロ‐２‐ピリミジニル）ピペラジン誘導体 |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| EP0238059B1 (en) | 1986-03-19 | 1993-06-16 | Kumiai Chemical Industry Co., Ltd. | 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same |
| ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| ATE94384T1 (de) | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| DE69434258T2 (de) | 1993-11-19 | 2006-01-19 | Janssen Pharmaceutica N.V. | Mikroverkapselte 1,2-benzazole |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6395939B1 (en) | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| EP1058678B1 (en) | 1998-02-26 | 2002-12-11 | Massachusetts Institute of Technology | Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| JP5035813B2 (ja) | 1998-07-10 | 2012-09-26 | マサチューセッツ インスティテュート オブ テクノロジー | 金属用のリガンドおよびそれらに基づいて改善された金属触媒法 |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| EP1140012B1 (en) | 1998-12-17 | 2004-03-03 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| PE20010052A1 (es) | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| US7071186B2 (en) * | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| CN1370176A (zh) | 1999-06-15 | 2002-09-18 | 布里斯托尔-迈尔斯斯奎布药品公司 | 取代的杂环稠合γ－咔啉 |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| BR0116429A (pt) | 2000-12-20 | 2006-05-09 | Bristol Myers Squibb Co | piridoindóis substituìdos como agonistas e antagonistas da serotonina |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| CN1854128B (zh) | 2001-04-24 | 2012-05-16 | 麻省理工学院 | 铜-催化的碳-杂原子键和碳-碳键的形成 |
| CA2453537A1 (en) | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | Therapeutic 1h-pyrido¬4,3-b|indoles |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| PL210119B1 (pl) | 2002-07-29 | 2011-12-30 | Alza Corp | Lek do leczenia stanu wrażliwego na paliperidon |
| KR20050032107A (ko) | 2002-08-02 | 2005-04-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 구리를 촉매로 한 탄소-헤테로원자 결합 및 탄소-탄소결합 형성방법 |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| US7109339B2 (en) | 2002-12-19 | 2006-09-19 | Bristol-Myers Squibb Company | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| SI1587789T1 (sl) | 2003-01-16 | 2009-02-28 | Acadia Pharm Inc | Selektivni inverzni agonisti serotoninskega 2A/2Creceptorja kot terapevtiki za nevrodegenerativne bolezni |
| US7462641B2 (en) | 2003-07-21 | 2008-12-09 | Smithkline Beecham Corporation | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| CA2564018A1 (en) | 2004-03-05 | 2005-10-13 | Pharma C S.A. | 8-phenoxy-.gamma. carboline derivatives |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| ES2367868T3 (es) | 2004-09-20 | 2011-11-10 | Mount Sinai School Of Medicine | Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad. |
| WO2006032999A1 (en) * | 2004-09-21 | 2006-03-30 | Pfizer Products Inc. | N-methyl hydroxyethylamine useful in treating cns conditions |
| MX2007006896A (es) | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| WO2006133261A2 (en) * | 2005-06-06 | 2006-12-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR101805914B1 (ko) | 2007-03-12 | 2017-12-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| WO2009017836A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| EP2262502A4 (en) * | 2008-02-05 | 2011-12-28 | Clera Inc | Compositions and methods for alleviating depression or improving cognition |
| PL2262505T3 (pl) | 2008-03-12 | 2015-04-30 | Intra Cellular Therapies Inc | Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej |
| JP6106361B2 (ja) | 2008-05-27 | 2017-03-29 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 睡眠障害および他の障害のための方法および組成物 |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| ES2727815T3 (es) | 2012-04-14 | 2019-10-18 | Intra Cellular Therapies Inc | Tratamiento del TEPT y de trastornos del control de impulsos |
| US10011602B2 (en) | 2012-07-06 | 2018-07-03 | The University Of Melbourne | Immunological reagents and uses therefor |
| PL2968320T3 (pl) | 2013-03-15 | 2021-05-17 | Intra-Cellular Therapies, Inc. | Związki organiczne |
| US9161061B2 (en) | 2013-03-15 | 2015-10-13 | Pictech Management Limited | Data storage and exchange device for color space encoded images |
| AU2014360452C1 (en) | 2013-12-03 | 2019-05-16 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR20170012210A (ko) | 2014-04-04 | 2017-02-02 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2015154030A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| IL309536B2 (en) | 2016-01-26 | 2025-07-01 | Intra Cellular Therapies Inc | Pharmaceutical preparation for injection containing (Sa10, Rb6)-3-)8-(4-fluorophenoxy)propyl)-b6, 7, 8, 9, 10, 10a- hexahydro-H1- pyrido[3',4' :4,5]pyrrolo[1,2,3 -de]quinoxalin-2(H3)-one |
| US10688097B2 (en) | 2016-03-25 | 2020-06-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| JP7013454B2 (ja) | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| JP7132939B2 (ja) | 2017-03-24 | 2022-09-07 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規組成物および方法 |
| EP3658145A4 (en) | 2017-07-26 | 2021-04-21 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| US11427587B2 (en) | 2017-07-26 | 2022-08-30 | Intra-Cellular Therapies, Inc. | Organic compounds |
-
2013
- 2013-04-14 ES ES13776189T patent/ES2727815T3/es active Active
- 2013-04-14 WO PCT/US2013/036512 patent/WO2013155504A1/en not_active Ceased
- 2013-04-14 US US14/394,469 patent/US11053245B2/en active Active
- 2013-04-14 RU RU2014145682A patent/RU2014145682A/ru not_active Application Discontinuation
- 2013-04-14 AU AU2013245702A patent/AU2013245702A1/en not_active Abandoned
- 2013-04-14 WO PCT/US2013/036514 patent/WO2013155505A1/en not_active Ceased
- 2013-04-14 JP JP2015505973A patent/JP2015514135A/ja not_active Withdrawn
- 2013-04-14 EP EP13776297.7A patent/EP2836213B1/en active Active
- 2013-04-14 US US14/394,467 patent/US9428506B2/en active Active
- 2013-04-14 EP EP13776208.4A patent/EP2836212A4/en not_active Ceased
- 2013-04-14 MX MX2014012374A patent/MX2014012374A/es unknown
- 2013-04-14 CN CN201380030774.2A patent/CN104519886B/zh not_active Expired - Fee Related
- 2013-04-14 EP EP20190036.2A patent/EP3791879A1/en active Pending
- 2013-04-14 US US14/394,470 patent/US20150080404A1/en not_active Abandoned
- 2013-04-14 EP EP13776189.6A patent/EP2836211B1/en active Active
- 2013-04-14 CA CA2870303A patent/CA2870303A1/en not_active Abandoned
- 2013-04-14 IN IN8562DEN2014 patent/IN2014DN08562A/en unknown
- 2013-04-14 WO PCT/US2013/036515 patent/WO2013155506A1/en not_active Ceased
- 2013-04-14 KR KR1020147031752A patent/KR20140146192A/ko not_active Withdrawn
- 2013-04-14 JP JP2015505972A patent/JP6242855B2/ja active Active
- 2013-04-14 JP JP2015505971A patent/JP6334511B2/ja active Active
-
2018
- 2018-06-05 JP JP2018107717A patent/JP2018168161A/ja not_active Withdrawn
-
2019
- 2019-09-27 US US16/585,251 patent/US11124514B2/en active Active
-
2020
- 2020-07-10 US US16/926,551 patent/US20200407362A1/en active Pending
- 2020-07-10 US US16/926,552 patent/US20210002280A1/en active Pending
-
2021
- 2021-03-08 JP JP2021035948A patent/JP2021098724A/ja active Pending
- 2021-08-18 US US17/405,736 patent/US11958852B2/en active Active
-
2023
- 2023-08-24 JP JP2023136052A patent/JP2023159345A/ja active Pending
-
2024
- 2024-03-11 US US18/601,923 patent/US20240208974A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08562A (enExample) | ||
| MX2012012277A (es) | Compuestos organicos. | |
| MX2021013564A (es) | Gamma-carbolinas fusionadas con heterociclo deuterado. | |
| MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
| MX365969B (es) | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. | |
| MX2016013046A (es) | Compuestos organicos. | |
| MX2020000968A (es) | Compuestos organicos. | |
| MX2020000967A (es) | Compuestos organicos. | |
| MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| MX2020009929A (es) | Compuestos organicos. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| MX2021007217A (es) | Compuesto organico. | |
| IN2015DN03921A (enExample) | ||
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| UA118562C2 (uk) | Модулятори рецептора cxcr7 | |
| PH12017501736A1 (en) | Indole derivatives | |
| TN2016000557A1 (en) | Pharmaceutical dosage forms | |
| GR1008169B (el) | Φαρμακευτικο σκευασμα περιεχον εναν αντιβακτηριακο παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου | |
| GB2569616B (en) | Sustained release oral pharmaceutical compositions of dicycloverine | |
| HK1220615A1 (zh) | 有机化合物 | |
| IN2013MU03838A (enExample) | ||
| GR1008082B (el) | Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου | |
| IN2013MU01239A (enExample) | ||
| IN2013MU01944A (enExample) |